Simple Truths About DIR Fees
Direct and indirect remuneration fees (DIR) as a percentage of gross drug cost have risen steadily from 11.3% in 2010 to 17.2% in 2015, according to the Centers for Medicare and Medicaid Services.
While pharmacy benefit managers (PBM) have been assessing DIR fees for years, this recent increase has negatively affected both retail and specialty pharmacies. In this whitepaper, Executive Director and head lobbyist at Frier Levitt Government Affairs, Ron Lanton III, Esq. outlines what is being done to minimize the impact of DIR fees and how policymakers are trying to address the issue.
While pharmacy benefit managers (PBM) have been assessing DIR fees for years, this recent increase has negatively affected both retail and specialty pharmacies. In this whitepaper, Executive Director and head lobbyist at Frier Levitt Government Affairs, Ron Lanton III, Esq. outlines what is being done to minimize the impact of DIR fees and how policymakers are trying to address the issue.
Download to learn:
Ron Lanton III, Esq.
- How changes in DIR fees are impacting your specialty pharmacy
- What is being done at the federal and state level to reduce DIR fees
- How your pharmacy can fight back against DIR fees

Ron Lanton III, Esq.
Executive Director and Head Lobbyist,
Frier Levitt Government Affairs, LLC
Ron Lanton has over 25 years of experience focused on government affairs including activities on the municipal, state, and federal government levels with 15 years dedicated to the healthcare sector. Ron founded the healthcare government affairs and lobbying firm True North Political Solutions. Ron is now the Executive Director and head lobbyist at Frier Levitt Government Affairs, LLC.
Request the Free PDF
Receive your copy of the white paper today!